Bioactivx
Bioactivx develops synthetic, animal-free biomaterial implants that accelerate wound healing and reduce scarring for acute and chronic wounds. Its flagship Bioactiv® Matrix skin substitute promotes tissue regeneration and inflammation control without requiring cold-chain storage, enabling use beyond sterile hospital environments. The company is preparing for regulatory submission and commercial launch.
- Medical Devices
- New Materials
- Healthcare Technology
- Biotechnology
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Millions of patients with acute and chronic wounds—including burns, ulcers, cuts, and abrasions—face slow healing, high infection risks, and permanent scarring with conventional wound care products that fail to actively support tissue regeneration. Many existing treatments rely on animal-derived materials, cold-chain logistics, and sterile operating environments, limiting access to advanced care.
Solution
Bioactivx provides a proprietary biomaterial platform using synthetic, animal-free materials with biological functions to create medical implants that support the body's natural healing process. The flagship Bioactiv® Matrix is a next-generation skin substitute designed to rapidly close both acute and chronic wounds by promoting skin regeneration and controlling inflammation. The product does not require cold-chain storage and is designed for application outside sterile operating theatre environments, potentially extending access to military, emergency, and remote healthcare settings. The company is preparing for regulatory submission and maintains a pipeline of additional advanced wound-care solutions, including foam dressings, antimicrobial cellulose, and a surgical wound closure device.
Target Audience
Primary customers are healthcare providers, wound-care centers, and hospitals treating burns, ulcers, and surgical wounds, as well as military, emergency response, and remote healthcare facilities seeking advanced wound management without cold-chain or sterile-environment dependencies.
Features
- Bioactiv® Matrix: next-generation skin substitute that promotes rapid wound closure through skin regeneration and inflammation control
- Fully synthetic, animal-free biomaterial platform with biological functionality, eliminating dependence on animal-derived collagen or skin grafts
- No cold-chain storage required and designed for application outside sterile operating environments, enabling use in resource-constrained settings
- Customizable matrix design enabling multiple treatment combinations for different wound types
- Pipeline products include Bioactiv® Foam (single-step integrated wound management), antimicrobial foam, antimicrobial cellulose, and Bioactiv® cellulose for wound packing
- Bioactiv® Surgical Wound Closure device for surgical applications
- Demonstrated outcomes in preclinical and first-in-human studies including faster wound closure, lower inflammation, and reduced scarring risk